Prevalence of blood donor women at risk of Hemolytic disease of the Fetus and Newborn in Southern Benin
Paper Details
Prevalence of blood donor women at risk of Hemolytic disease of the Fetus and Newborn in Southern Benin
Abstract
Hemolytic Disease of the Fetus and Newborn (HDFN) is a genetic disorder caused by blood group incompatibility, particularly Rh (D) antigen, in the parental couple. This study aimed to determine the prevalence of blood donor women exposed to the risk of HDFN among 913 blood donors in the southern region of Benin. The study was conducted from March to June 2022 at the departmental blood transfusion centers in the Atlantic and Littoral regions. Samples were collected following the procedures of the National Blood Transfusion Agency (NBTA), using tube and microplate agglutination tests. Among the donors, 260 (28.5%) were women aged between 18 and 52 years. The O+ blood group donors constituted the largest proportion, accounting for 42% of the sample. Nearly one-third (33.3%) of the female blood donors were Rh (D) negative, putting them at risk of HDFN. Most of these women were of reproductive age, with a significant representation in the 20-30 age groups (42.1%). This study revealed that one-third of female blood donors in the Atlantic and Littoral regions were at risk of giving birth to an infant affected by HDFN. These findings underscore the importance of raising awareness and implementing preventive measures to mitigate the risks associated with this condition.
Agarwal K, Rana A, Ravi AK. 2014. Treatment and Prevention of Rh Isoimmunization. J. Fetal Med. 1, 81-88.
Avent ND, Reid ME. 2000. The Rh blood group system: a review. Blood 95, 375-387.
Bearak J, Popinchalk A, Ganatra B, Moller A-B, Tunçalp Ö, Beavin C, Kwok L, Alkema L. 2020. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019. The Lancet Global Health 8, e1152-e1161.
Blanco S, Giacomi VS, Slobodianiuk LG, Frutos MC, Carrizo LH, Fanin GE, Culasso JM, Gallego SV. 2018. Usefulness of Non-Invasive Fetal RHD Genotyping towards Immunoprophylaxis Optimization. Transfus Med Hemother 45, 423-428.
Boulkadid MEH, Brouk H, Ouelaa H. 2016. Fréquences phénotypique et allélique des systèmes ABO, Rhésus et Kell dans l’Est algérien. Transfusion Clinique et Biologique 23, 294-295.
Branger B, Winer N. 2006. Épidémiologie de l’allo-immunisation anti-D pendant la grossesse. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 35, 87-92.
Castleman JS, Moise Jr KJ, Kilby MD. 2021. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. British Journal of Haematology 192, 425-432.
Clarke CA, Evans DA, Harris R, McConnell RB, Woodrow JC. 1968. Genetics in medicine: a review. Immunogenetics. Genetics of immunological deficiency states. Q J Med 37, 220-241.
Dziegiel MH, Krog GR, Hansen AT, Olsen M, Lausen B, Nørgaard LN, Bergholt T, Rieneck K, Clausen FB. 2021. Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn. Transfusion Medicine and Hemotherapy 48, 306-315.
El Khabous S. 2018. La prévalence des phénotypes des systèmes ABO, RH ET KELL chez 10000 donneurs de sang AU CTS DE L’HMIM-V Rabat- Maroc. (Thesis).
Minon JM, Gerard CH, Chantraine F, Nisolle M. 2015. Anti-D Prophylaxis Reviewed in the Erea of Foetal RHD Genotyping. Journal of Blood Disorders & Transfusion 6, 1-6.
Kanko TK, Woldemariam MK. 2021. Prevalence of Rhesus D negativity among reproductive age women in Southern Ethiopia: a cross-sectional study. BMC Women’s Health 21, 161.
Khalloufi A, Imrani ZT, Chegri M. 2017. Étude de la prévalence des groupes sanguins ABO, Rh et Kell: À propos de 3589 dons de sang dans une région du centre du Maroc. Research fr4.
Koelewijn JM, Vrijkotte TGM, Van Der Schoot CE, Bonsel GJ, De Haas M. 2008. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 48, 941-952.
Loua A, Lamah MR, Haba NY, Camara M. 2007. Fréquence des groupes sanguins ABO et rhésus D dans la population guinéenne. Transfusion Clinique et Biologique 14, 435-439.
Souabni SA, Habib BE, Oubahha I, Baqali JE, Aboulfalah A, Soummani A. 2021. Allo-immunisation fœto-maternelle sévère : à propos d´un cas et revue de la littérature. Pan Afr Med J 38, 67.
Tagny CT, Fongué VF, Mbanya D. 2009. The erythrocyte phenotype in ABO and Rh blood groups in blood donors and blood recipients in a hospital setting of Cameroon: adapting supply to demand. Rev Med Brux 30, 159-162.
Tsochandaridis M, D’Ercole C, Gabert J, Lévy-Mozziconacci A. 2016. Tests non invasifs en dehors des maladies génétiques : génotypage non invasif du groupe sanguin fœtal RHD, RHCE et KEL1 sur plasma maternel. Rev. med. perinat 8, 62-66.
Woodrow JC, Clarke CA, McConnell RB, Towers SH, Donohoe WT. 1971a. Prevention of Rh-haemolytic disease: results of the Liverpool “low-risk” clinical trial. Br Med J 2, 610-612.
Woodrow JC, Clarke CA, McConnell RB, Towers SH, Donohoe WTA. 1971b. Prevention of Rh-haemolytic Disease: Results of the Liverpool “Low-risk” Clinical Trial. BMJ 2, 610-612.
Zipursky A, Hull A, White FD, Israels LG. 1959. Foetal erythrocytes in the maternal circulation. Lancet 1, 451-452.
Danhouegnon Dognonvi, Segbo Julien A. Gaétan, Degbey Cyriaque, Gbenanhou Herve, Migan ADF. Marcos, Alowakinnou Christelle, Padonou Edgard, Akpovi D. Casimir, 2023. Prevalence of blood donor women at risk of Hemolytic disease of the Fetus and Newborn in Southern Benin. Int. J. Biosci., 23(5), 101-106.
Copyright © 2023 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.